| |
THE COMPANY
ApopLogic Pharmaceuticals, LLC is a startup phase biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products that target apoptotic cell death pathways found in cancers, leukemias and lymphomas. The Company was formed in 2006 to capitalize on the intellectual property of its Founding Scientists and University of Colorado Cancer Center members, Richard C. Duke, Ph.D., Donald Bellgrau, Ph.D., Paul A. Bunn, M.D., Daniel Chan, Ph.D., Lajos Gera, Ph.D., Jaime Modiano, D.V.M., Ph.D. and John Stewart, Ph.D. Put most simply, ApopLogic is inducing rapidly dividing cells to commit suicide.
The Company's products are:
Breceptin: A novel neuropeptide growth factor receptor antagonist that targets a broad range of cancers.
Cytonil: A proprietary combination of a cell-type specific growth factor and a cell signaling agonist to treat Sezary leukemia, cutaneous T cell lymphoma and psoriasis.
Fasaret: A proprietary therapy based on Fas ligand, an apoptotic cell death-inducing molecule with unique pro- inflammatory properties, for the treatment of cancers.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
Richard C. Duke, Ph.D., President and CEO
ApopLogic Pharmaceuticals, LLC
12635 East Montview Blvd.
Aurora, CO 80010
Email: richard.duke@apoplogic.com |
